Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger

The $18-per-share offer represents a 25% premium over AMAG's stock price as of Aug. 2, but it's not enough to return the anemia drug maker's valuation to the days just before it unveiled the Allos deal on July 20.